中国实验血液学杂志最新文献

{"title":"[Prognostic Significance of Endothelial Activation and Stress Index in Mantle Cell Lymphoma].","authors":"Xin-Yue Zhou, Zhi-Qin Yang, Jin Hu, Feng-Yi Lu, Qian-Nan Han, Huan-Huan Zhao, Wen-Xia Gao, Yu-Han Ma, Hu-Jun Li, Zhen-Yu Li, Kai-Lin Xu, Wei Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.018","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.018","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the predictive value of endothelial activation and stress index (EASIX) for the prognosis of patients with mantle cell lymphoma (MCL).</p><p><strong>Methods: </strong>A retrospective analysis was conducted to assess prognosis and compare the clinical features of patients diagnosed with MCL who were admitted to the Affiliated Hospital of Xuzhou Medical University from January 2010 to June 2023, had therapeutic indications and received standard treatment.</p><p><strong>Results: </strong>A total of 66 patients were included and divided into high EASIX group and low EASIX group, according to a cutoff value of 0.97 determined by the receiver operating characteristic (ROC) curve. Multivariate Cox regression analysis showed that prealbumin <0.2 g/L, high EASIX, and ECOG PS score ≥2 were independent risk factors influencing overall survival (OS) in MCL patients. The median OS of patients in the high and low EASIX group was 13.0 and 37.5 months, and the median progression-free survival was 8.8 and 26.0 months, respectively. The proportions of patients with ECOG PS score ≥2 and prealbumin <0.2 g/L at onset significantly increased in the high EASIX group compared to those in the low EASIX group.</p><p><strong>Conclusion: </strong>At the time of initial diagnosis, EASIX can serve as an independent prognostic indicator impacting OS in patients with MCL. Furthermore, patients in the high EASIX group experience a poorer prognosis and shorter survival duration compared with those in the low EASIX group.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1051-1056"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Predictive Value of Sarcopenia for Therapeutic Response and Prognosis in Patients with Acute Myeloid Leukemia].","authors":"Juan Zhao, Jia Li, Ling-Ling Qian, Zuo-Feng Ding, Li Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.012","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.012","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of sarcopenia on therapeutic response and prognosis of newly diagnosed acute myeloid leukemia (AML) patients, and reveal its predictive value for the clinical outcomes of AML patients.</p><p><strong>Methods: </strong>A total of 122 AML patients who were initially diagnosed and treated with induction chemotherapy at the Department of Hematology in the Affiliated Hospital of Nantong University from January 2017 to December 2020 were included in this study. The sarcopenia was diagnosed by measuring body composition parameters with multifrequency bioelectrical impedance analyzer, and all AML patients were divided into sarcopenia and non-sarcopenia groups. Kaplan-Meier curves and log-rank test were used to compare the survival difference between the two groups. The relationship between sarcopenia and overall survival (OS) of AML patients was further determined by the univariate and multivariate Cox regression analysis.</p><p><strong>Results: </strong>Among 122 AML patients, 46 (37.7%) were diagnosed with sarcopenia before induction chemotherapy. The body mass index (BMI) of patients with sarcopenia was significantly lower than that of non-sarcopenia patients ( <i>t</i> =4.258, <i>P</i> <0.001), and the complete response (CR) and partial response (PR) rates of sarcopenia patients after induction chemotherapy were significantly lower than those of nonsarcopenia patients (χ²=6.348, <i>P</i> =0.042). Kaplan-Meier curves showed that sarcopenic patients had a shorter OS than non-sarcopenic patients, and the median OS of the two groups were 20.7 (95%<i>CI</i> : 12.6-27.8) months and 27.8 (95%<i>CI</i> : 22.3-31.9) months, respectively (χ²= 5.659, <i>P</i> =0.017). Subgroup analysis indicated that the median OS of sarcopenic and non-sarcopenic AML patients who received standard induction chemotherapy were 12.2 (95%<i>CI</i> : 5.4-24.7) months and 26.1 (95%<i>CI</i> : 16.7-35.4) months, respectively (χ²=3.949, <i>P</i> =0.047). The multivariate Cox regression analysis revealed that sarcopenia (<i>HR</i>=1.671, 95%<i>CI</i> : 1.034-2.701, <i>P</i> =0.036) was an independent predictor for poor prognosis in AML patients.</p><p><strong>Conclusion: </strong>Sarcopenia is significantly associated with low response rate of induction chemotherapy and poor prognosis in AML patients, and it might be an useful tool for predicting the clinical outcome of AML patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1016-1022"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Role of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Lymphoma--Review].","authors":"Xing-Hui Jiang, Yi-Jian Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.043","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.043","url":null,"abstract":"<p><p>Lymphoma is a malignant tumor originating from lymphatic tissue, which can be roughly divided into two types: Hodgkin's lymphoma and non-Hodgkin's lymphoma. It has the characteristics of high recurrence rate, high mortality rate, and short survival time. Tumor cells in lymphoma form a tumor microenvironment (TME) that inhibits host anti-tumor immunity with surrounding immune cells, while tumor-associated macrophages (TAMs) are a key cell in TME. TAMs promote immune evasion of tumor cells in some ways by producing various cytokines and/or abnormal expression of immune checkpoint molecules. Programmed death receptor-1 (PD-1) and its ligand 1 (PD-L1) are important negative regulatory factors for immune cell activation. Recent studies have shown that anti-PD-1/PD-L1 therapy represents a new strategy for lymphoma immunotherapy. This article will focus on the role and expression of TAMs and PD-1/PD-L1 in lymphoma, and explore the efficacy of anti-PD-1/PD-L1 immunotherapy in different types of lymphoma.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1217-1221"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Family Study and Blood Transfusion of a Patient with Hereditary Coagulation Factor XI Deficiency].","authors":"Ya-Xin Han, Ying Ren, Rong Zhao, Ai-Chun Qu, Zhi-Gang Yang","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.035","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.035","url":null,"abstract":"<p><strong>Objective: </strong>To investigate a family with hereditary coagulation factor XI (FXI) deficiency, identify its possible genetic etiology, analyze the bleeding risk of the proband, and provide a blood transfusion regimen.</p><p><strong>Methods: </strong>The blood samples from the family members were collected, and the coagulation parameters of the proband and her family members were detected. Whole-exome sequencing was performed on the blood samples of the proband to identify gene variants, and validate the variants in the family using Sanger sequencing. Bioinformatics softwares were used to analyze the conservation of amino acid variant sites and the impact of the variations on protein function. The pathogenicity of the variant sites was analyzed according to the genetic variation classification criteria and guidelines of the American College of Medical Genetics and Genomics (ACMG). Thromboelastography (TEG) was used to assess the coagulation function of the family members and evaluate the transfusion regimen and its efficacy in the proband.</p><p><strong>Results: </strong>The activated partial thromboplastin time (APTT) of the proband was significantly prolonged to 96.7 seconds, and FXI activity (FXI: C) and FXI antigen (FXI: Ag) decreased to 1.3% and 1%, respectively, both of which were extremely reduced. The FXI: C of the proband's father was also significantly lower than the normal value. The TEG results showed that the coagulation function of the proband was reduced, while the coagulation function of other family members was normal. The <i>F11</i> gene of the proband exhibited compound heterozygous variants of c.738G>A (p.Trp246 *) and c.1288G>A (p.Ala430Thr). The proband's father carried a heterozygous missense variant of c.1288G>A (p.Ala430Thr), while her mother, her eldest daughter, and her youngest daughter carried a heterozygous nonsense variant of c.738G>A (p.Trp246 *). According to the ACMG genetic variation classification criteria and guidelines, c.738G>A (p.Trp246 *) is classified as a pathogenic variant (PVS1+PS3-Moderate+PP4), and c.1288G>A (p.Ala430Thr) is classified as a possible pathogenic variant (PS3-Moderate+PM1+PM3_Srong+PP4). p.Trp246 and p.Ala430 are highly conserved across different species. Swiss PdbViewer software analysis showed that p.Ala430Thr variant caused a change in the number of hydrogen bonds in FXI protein, affecting protein function. The following transfusion regimen was determined through TEG evaluation in vitro: 600 ml of fresh frozen plasma (FFP) was administered 24 hours before surgery to prevent bleeding. And there was no significant bleeding during or after the surgery.</p><p><strong>Conclusion: </strong>The heterozygous nonsense variant ofc.738G>A (p.Trp246 *) and the heterozygous missense variant of c.1288G>A (p.Ala430Thr) in the <i>F11</i> gene are the pathogenic factors of this hereditary FXI deficiency family.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1161-1167"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Synergistic Effect of Combination of Flumatinib with Chidamide in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia].","authors":"Chen-Yan Yang, Chan Yang, Zheng Ge","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.004","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.004","url":null,"abstract":"<p><strong>Objective: </strong>To explore the synergistic effect of flumatinib (FLU) combined with histone deacetylase inhibitor chidamide (CHI) and underlying mechanism on Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL) SUP-B15 cells.</p><p><strong>Methods: </strong>CCK-8 method was used to examine the effects of FLU, CHI alone and combination therapy on the proliferation of SUP-B15 cells. Flow cytometry was utilized to analyze the cell cycle and apoptosis. RT-qPCR and Western blot methods were performed to detect target gene expression.</p><p><strong>Results: </strong>FLU combined with CHI significantly inhibited the proliferation, induced G₀/G₁ phase arrest, and increased the apoptosis rate in SUP-B15 cells compared with FLU and CHI alone. The 50 genes were identified by overlapping the two drugs' targets of action with Ph⁺ ALL oncogenic genes in the public databases, and <i>p53</i> and <i>c-Myc</i> transcription factors and PI3K/AKT signaling pathways were enriched in the overlapped genes. The combination of FLU and CHI significantly reduced the mRNA level of <i>BCR::ABL</i> fusion gene, up-regulated the protein and mRNA levels of p53, BAX, and Caspase-3, and down-regulated the protein and mRNA levels of c-Myc, PIK3CA, PIK3CB, and AKT2 compared with single-drug therapy. The analysis of GEO database and our center cohort showed that <i>c-Myc, PIK3CA, PIK3CB</i>, and <i>AKT2</i> were significantly up-regulated while <i>p53</i> was down-regulated in Ph⁺ ALL patients compared to healthy controls.</p><p><strong>Conclusion: </strong>FLU combined with CHI synergistically inhibits cell proliferation, promotes apoptosis, and induces cycle arrest by targeting the PI3K/AKT signaling pathway through the <i>p53/c-Myc</i> axis in Ph⁺ ALL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"951-960"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Features and Prognosis of Primary Tonsil Lymphoma].","authors":"Dan Luo, Qi-Miao Shan, Hua Ding, Jiao Liu, Zi-Qing Huang, Feng Zhu","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.016","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.016","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical features and prognostic factors of primary tonsil lymphoma (PTL).</p><p><strong>Methods: </strong>The clinical data of 41 patients diagnosed with PTL and treated in the Affiliated Hospital of Xuzhou Medical University from January 2015 to December 2022 were collected and retrospectively analyzed. Their clinical features and prognostic factors were analyzed.</p><p><strong>Results: </strong>All the 41 patients were newly diagnosed with PTL, and the median age of onset was 58(19-85) years. Among them, 19 patients started with pharyngeal pain, 12 patients presented with dysphagia, 8 patients presented with pharyngeal mass, and 2 patients presented with blurred articulation. The most common pathological type was diffuse large B-cell lymphoma (24 cases, 58.54%). All patients received chemotherapy, and 3 patients were combined with hematopoietic stem cell transplantation. Among 41 patients, 11 (26.83%) achieved complete response, 14 (34.15%) achieved partial response, and the total response rate was 60.98% (25/41). The median follow-up time was 37(6-107) months, the 5-year overall survival (OS) rate was 70.81% and 5-year progression-free survival (PFS) rate was 66.20%. Univariate analysis showed that B symptoms, Ki-67, β₂-MG and IPI score had significant effects on PFS and OS of patients (all <i>P</i> < 0.05). Multivariate analysis showed that IPI score was an independent risk factor for PFS and OS of patients (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The clinical manifestations of PTL lack specificity, and the prognosis is relatively good. Most patients can achieve long-term survival after treatment. IPI score is related to the prognosis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1042-1046"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effects of Total Body Irradiation with ⁶⁰ Co Gamma Ray at Different Dose Rates on Hematopoietic and Immune Cells in Mice].","authors":"Hui Shu, Ya Dong, Xue-Wen Zhang, Xing Shen, Shuang Xing, Zu-Yin Yu","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.038","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.038","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the effect of irradiation dose rate of &lt;sup&gt;60&lt;/sup&gt;Co γ-ray on hematopoietic and immune cells in total body irradiation (TBI) mice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;After TBI with 8 Gy &lt;sup&gt;60&lt;/sup&gt;Co γ-ray at three irradiation dose rates of 0.027, 0.256 and 0.597 Gy/min, the survival and change of body weight of C57BL/6J mice were observed within 30 days. The peripheral blood parameters were examined at each time point within 30 days post-irradiation. The hematopoietic stem/progenitor cell counts of mice were examined on the 10&lt;sup&gt;th&lt;/sup&gt; and 30&lt;sup&gt;th&lt;/sup&gt; day post-irradiation by flow cytometry, as well as the proportions of immune cells in peripheral blood, bone marrow and spleen of mice on the 30&lt;sup&gt;th&lt;/sup&gt; day post-irradiation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;After TBI with 8 Gy &lt;sup&gt;60&lt;/sup&gt;Co γ-ray, the 30-day survival rate of high dose-rate group was 0, which was significantly lower than 90% of medium dose-rate group and 100% of low dose-rate group (both &lt;i&gt;P&lt;/i&gt; &lt; 0.001). The peripheral blood parameters of all three groups showed a sharp decline → low value → gradually recovering trend. The count of white blood cell, neutrophil, lymphocyte, red blood cell, platelet and hemoglobin level in the high dose-rate and medium dose-rate groups were significantly lower than those in the low dose-rate group on day 7-18 post-irradiation (all &lt;i&gt;P&lt;/i&gt; &lt; 0.05), but there were no significant differences between the high dose-rate and medium dose-rate groups (&lt;i&gt;P&lt;/i&gt; &gt;0.05). On the 10&lt;sup&gt;th&lt;/sup&gt; day after irradiation, the proportion and number of bone marrow hematopoietic stem/progenitor cells (including LK, LSK, LT-HSC, ST-HSC, and MPP cells) in the low dose-rate and medium dose-rate groups were significantly decreased compared to those in the normal group (all &lt;i&gt;P&lt;/i&gt; &lt; 0.05), but there were no significant differences between the two groups (&lt;i&gt;P&lt;/i&gt; &gt;0.05). On the 30&lt;sup&gt;th&lt;/sup&gt; day after irradiation, LSK, LT-HSC, ST-HSC and MPP cells in the low dose-rate group recovered to normal levels, while those in the medium dose-rate group were still significantly lower than those in the low dose-rate group (all &lt;i&gt;P&lt;/i&gt; &lt; 0.001). The results of bone marrow and peripheral immune cell tests on the 30&lt;sup&gt;th&lt;/sup&gt; day after irradiation showed that the ratios of T and B lymphocytes in the low dose-rate and medium dose-rate groups were reduced compared to that in the normal group (both &lt;i&gt;P&lt;/i&gt; &lt; 0.05), while the ratio of neutrophils was increased (&lt;i&gt;P&lt;/i&gt; &lt; 0.01). The trend of changes in the spleen and peripheral blood was consistent.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The degree of hematopoietic and immune cell damage in mice after TBI with 8 Gy &lt;sup&gt;60&lt;/sup&gt;Co γ-ray is related to the dose rate, and low dose-rate irradiation can reduce the damage in the animal model. Therefore, choosing the appropriate dose rate of irradiation is a key factor in establishing an objective and reliable experimental animal mo","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1181-1189"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristic of Castleman Disease with Renal and Orbit Involvement].","authors":"Yin-Qian Liu, You-Hai Xu, He-Sheng He","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.042","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.042","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical characteristics, diagnosis, and treatment methods of one patient with idiopathic multicentric Castleman disease (iMCD), in order to strengthen the understanding of this rare disease.</p><p><strong>Methods: </strong>The clinical manifestations, diagnosis and treatment process, and prognosis of one patient with iMCD admitted to our hospital were retrospectively analyzed.</p><p><strong>Results: </strong>The patient was a 45-year-old female with swollen bilateral orbit, edema of lower limbs, multiple serosal cavity effusion, thrombocytopenia, renal insufficiency, and multiple lymph node enlargement. Lymph node biopsy suggested mixed type of Castleman disease. Combined with pathology, imaging and laboratory examination, the patient was finally diagnosed with mixed type of iMCD. After six cycles of R-COP regimen chemotherapy, the patient achieved complete remission.</p><p><strong>Conclusions: </strong>Castleman disease with renal and orbit involvement is rare in clinic and easy to be misdiagnosed. It should be distinguished from lymphoma. The patient has been treated with R-COP regimen, and obtained good short-term efficacy.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"899-905"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristics and Prognostic Analysis of Peripheral T-Cell Lymphoma, Not Otherwise Specified].","authors":"Guo-Xiang Chen, Jian-Shu Hao, Xue Bai, Qing-Qing Zhang, Hai-Xia An, Xiu-Juan Huang, Yan-Qing Sun","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.019","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.019","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and prognosis of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS).</p><p><strong>Methods: </strong>Clinical data of 10 patients with PTCL-NOS in Gansu Provincial Hospital from May 2016 to June 2023 were collected. The treatment outcomes were evaluated, and the factors affecting prognosis were analyzed.</p><p><strong>Results: </strong>The median age of onset for the 10 patients was 60.7 (47-75) years, with 7 males and 3 females. Nine cases received chemotherapy, while one case died suddenly after diagnosis, and the median course of chemotherapy was 6.9 (1-13) courses. Assessing the efficacy, 3 patients achieved complete remission (CR) while 7 patients showed progression. Age, sex, lactate dehydrogenase (LDH) level, Ki-67 and the presence of hemophagocytic lymphohistocytosis (HLH) were not statistically correlated with CR rate ( <i>P</i> >0.05). Patients with IPI score 3-5, and Ann Arbor stage III-IV had statistically lower CR rates (both <i>P</i> <0.05). Age, B symptoms, LDH level ,hemoglobin, Ki-67 index and PLR value were not statistically correlated with overall survival (OS) time ( <i>P</i> >0.05). Male, platelet <150×10⁹/L, IPI score 3-5, Ann Arbor stage III-IV, presence of HLH, NLR≥4.05, and LMR <2.81 were statistically correlated with shorter OS (all <i>P</i> <0.05). Among the 10 patients, 3 cases have survived and are still in CR status, while 7 cases have died, with a median survival time of 7.5 (1-85) months.</p><p><strong>Conclusions: </strong>Patients with IPI score 3-5 and Ann Arbor stage III-IV have low CR rate and poor prognosis. The OS of patients who are male, with platelet <150×10⁹/L, IPI score 3-5, Ann Arbor stage III-IV, complication of HLH, NLR≥4.05, and LMR <2.81 is short, and prognosis is poor.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"753-759"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Study of Ibrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma].","authors":"Yu-Ning Yao, Hao Jiang, Lu-Min Tang, Ye Lou","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.023","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.023","url":null,"abstract":"<p><strong>Objective: </strong>To study the clinical effects of ibrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL).</p><p><strong>Methods: </strong>A total of 101 patients with RRDLBCL in Daqing People's Hospital from September 2019 to September 2022 were selected. 45 patients were received ibrutinib monotherapy, 36 patients were received a combination therapy of ibrutinib, rituximab, and lenalidomide, and 20 patients were received a combination therapy of ibrutinib and lenalidomide. The clinical effects were observed.</p><p><strong>Results: </strong>The median duration of treatment for all patients was 4 (2-9) months. The disease control rates(DCR) and objective response rates(ORR) in the ibrutinib monotherapy group were 46.67% and 26.67%, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the DCR and ORR were 69.44% and 44.44%, respectively. In the combination therapy group of ibrutinib and lenalidomide, the DCR and ORR were 60.00% and 35.00%, respectively. The DCR and ORR in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (<i>P</i> < 0.05). There were no significant differences in DCR and ORR between the combination therapy group of ibrutinib and lenalidomide and the ibrutinib monotherapy group (<i>P</i> >0.05). The median follow-up time of all patients was 15 (5-35) months, with a median overall survival(OS) of 21.0 (15.8-26.2) months and a median progression-free survival(PFS) of 14.0 (12.1-15.9) months. In the ibrutinib monotherapy group, the median OS and PFS were 15.0 (12.1-17.9) months and 12.0 (11.0-13.0) months, respectively. In the combination therapy group of ibrutinib and lenalidomide, the median OS and PFS were 22.0 (13.3-30.7) months and 16.0 (14.1-19.7) months, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the median OS and PFS were 23.0 (19.7-26.3) months and 17.0 (14.8-19.1) months, respectively. The median OS and PFS in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (<i>P</i> < 0.05). There were no significant differences in median OS and PFS between the combination therapy group of ibrutinib and lenalidomide and the combination therapy group of ibrutinib, rituximab, and lenalidomide (<i>P</i> >0.05). Hematological adverse reactions included neutropenia in 14 cases (13.86%), thrombocytopenia in 16 cases (15.84%), and leukopenia in 13 cases (12.87%). Non-hematological adverse reactions mainly included nausea and vomiting in 33 cases (32.67%) and fatigue in 44 cases (43.56%).</p><p><strong>Conclusion: </strong>Ibrutinib has certain clinical effects and good safety in the treatment of RRDLBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"784-788"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}